About Adenylosuccinate synthetase isozyme 1
Adenylosuccinate synthetase isozyme 1 (ADSS1) is a protein
from Homo sapiens identified by UniProt accession
Q8N142, 457 residues long.
MolForge cross-references it against 0 known binders and
46 disease associations.
Target properties
| Protein name | Adenylosuccinate synthetase isozyme 1 |
| UniProt accession | Q8N142 |
| Gene | ADSS1 |
| Organism | Homo sapiens |
| Length | 457 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (46)
Diseases linked to this target (Open Targets).
- myopathy · score 0.54
- fetal akinesia deformation sequence · score 0.34
- fetal akinesia deformation sequence 1 · score 0.34
- arthrogryposis multiplex congenita · score 0.34
- lymphatic system disease · score 0.20
- genetic disorder · score 0.19
- peak expiratory flow · score 0.14
- breast carcinoma · score 0.12
- forced expiratory volume · score 0.11
- endometrial endometrioid carcinoma · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8N142-F1 | alphafold | PREDICTED | 92.71 | — |
Amino-acid sequence (457 residues)
MSGTRASNDR PPGAGGVKRG RLQQEAAATG SRVTVVLGAQ WGDEGKGKVV DLLATDADII SRCQGGNNAG HTVVVDGKEY DFHLLPSGII NTKAVSFIGN GVVIHLPGLF EEAEKNEKKG LKDWEKRLII SDRAHLVFDF HQAVDGLQEV QRQAQEGKNI GTTKKGIGPT YSSKAARTGL RICDLLSDFD EFSSRFKNLA HQHQSMFPTL EIDIEGQLKR LKGFAERIRP MVRDGVYFMY EALHGPPKKI LVEGANAALL DIDFGTYPFV TSSNCTVGGV CTGLGIPPQN IGDVYGVVKA YTTRVGIGAF PTEQINEIGG LLQTRGHEWG VTTGRKRRCG WLDLMILRYA HMVNGFTALA LTKLDILDVL GEVKVGVSYK LNGKRIPYFP ANQEMLQKVE VEYETLPGWK ADTTGARRWE DLPPQAQNYI RFVENHVGVA VKWVGVGKSR ESMIQLF
Explore Adenylosuccinate synthetase isozyme 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets